The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH(2)(2+))[PtCl6].H2O and (RosH(2)(2+))(2)[PtCl6]Cl-2.4H(2)O

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F07%3A00033220" target="_blank" >RIV/00216224:14310/07:00033220 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH(2)(2+))[PtCl6].H2O and (RosH(2)(2+))(2)[PtCl6]Cl-2.4H(2)O

Popis výsledku v původním jazyce

A series of Pt(IV) complexes with cytokinins or CDK-inhibitors derived from 6-benzylaminopurine (Bap) of the composition [Pt-IV(LH+)Cl-5] (1-14), where LH+ stands for protonated form of the Bap derivative (1-12), Boh = 6-(benzylamino)-2-[(3-hydroxypropyl)amino]-9-isopropylpurine, bohemine (13) and Ros = 6-(benzylamino)-2-[(1-hydroxymethylpropyl)amino]-9-isopropylpurine, roscovitine (14), have been prepared. They have been fully characterized by microanalysis, conductivity, FT-IR, H-1, C-13, N-15 and Pt-195 NMR and ES+ mass spectroscopy. All of the compounds have been tested in vitro for their cytotoxicity against four human cancer cell lines: malignant melanoma (G361), osteogenic sarcoma (HOS), chronic myelogenous erythroleukemia (K562) and breast adenocarcinoma (MCF7). The molecular structures of two ionic pair compounds (BohH(2)(2+))[PtCl6] center dot H2O (15) and (RosH(2)(2+))(2)[PtCl6]Cl-2 center dot 4H(2)O (16) have been determined by a single crystal X-ray analysis.

Název v anglickém jazyce

The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH(2)(2+))[PtCl6].H2O and (RosH(2)(2+))(2)[PtCl6]Cl-2.4H(2)O

Popis výsledku anglicky

A series of Pt(IV) complexes with cytokinins or CDK-inhibitors derived from 6-benzylaminopurine (Bap) of the composition [Pt-IV(LH+)Cl-5] (1-14), where LH+ stands for protonated form of the Bap derivative (1-12), Boh = 6-(benzylamino)-2-[(3-hydroxypropyl)amino]-9-isopropylpurine, bohemine (13) and Ros = 6-(benzylamino)-2-[(1-hydroxymethylpropyl)amino]-9-isopropylpurine, roscovitine (14), have been prepared. They have been fully characterized by microanalysis, conductivity, FT-IR, H-1, C-13, N-15 and Pt-195 NMR and ES+ mass spectroscopy. All of the compounds have been tested in vitro for their cytotoxicity against four human cancer cell lines: malignant melanoma (G361), osteogenic sarcoma (HOS), chronic myelogenous erythroleukemia (K562) and breast adenocarcinoma (MCF7). The molecular structures of two ionic pair compounds (BohH(2)(2+))[PtCl6] center dot H2O (15) and (RosH(2)(2+))(2)[PtCl6]Cl-2 center dot 4H(2)O (16) have been determined by a single crystal X-ray analysis.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CA - Anorganická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Polyhedron

ISSN

0277-5387

e-ISSN

—

Svazek periodika

26

Číslo periodika v rámci svazku

18

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—